40.35
+0.75%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PolyPeptide Group
Its shares trade on SIX under the ticker PPGN.SW. It has been listed since 29 April 2021. In the fiscal year to 31 December 2025, it reported revenue of €368.6m and a net loss of €20.0m. At that date it held total assets of €776.2m and shareholders' equity of €320.1m.
PolyPeptide Group AG is a contract development and manufacturing organization for clinical and approved commercial-stage peptide drug substances used in peptide-based therapeutics. The company is headquartered in Zug, Zug. The company went IPO on 2021-04-29.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 29 Apr 2021
- Employees
- 1,156
- Website
- polypeptide.com ↗
Leadership
Pay as last reported
- Mr. Peter WildenNon-Executive Chairman of the Board, since 2021CHF 337,042
- Mr. Juan-Jose GonzalezChief Executive OfficerCHF 2.5m
- Mr. Patrick AebischerNon-Executive Vice Chairman of the Board, Lead Independent DirectorCHF 224,317
- Mr. Marc AugustinChief Financial Officer
- Ms. Christina Del VecchioGeneral Counsel, Corporate Secretary
- Mr. Jens FrickeDirector Global Operations
- Ms. Jane SalikNon-Executive Director, since 2006CHF 140,038
- Mr. Erik SchroppNon-Executive Director
- Dr. Beat In-AlbonNon-Executive Independent DirectorCHF 168,641
- Dr. Philippe WeberNon-Executive Independent DirectorCHF 211,398
- Mr. Michael StaheliHead of Investor Relations and Corporate Communications, since 2020
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 35
- Social
- 88
- Governance
- 65
- Direct emissions (scope 1)
- 5,834 t
- Energy emissions (scope 2)
- 9,395 t
- Value chain emissions (scope 3)
- 64,667 t
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PolyPeptide Group AG has a strong reputation in the biotechnology industry, known for its expertise in peptide manufacturing and synthesis.
- The company has an extensive portfolio of high-quality products, providing a competitive advantage over rivals.
- PolyPeptide Group AG invests significantly in research and development activities, allowing for continuous innovation and the development of new products.
- The company has a global presence, with production facilities and sales offices strategically located in key markets.
Weaknesses
- PolyPeptide Group AG may face challenges in maintaining cost competitiveness due to the complex nature of peptide manufacturing processes.
- The company's heavy reliance on a few key customers poses a risk, as losing any of these customers could significantly impact revenue.
- PolyPeptide Group AG heavily relies on advanced technology and processes in its operations, which may be susceptible to disruptions or obsolescence.
Opportunities
- The increasing demand for peptide-based therapeutics provides a growth opportunity for PolyPeptide Group AG to expand its product offerings.
- International expansion into emerging markets, where demand for biotechnology products is growing, presents an opportunity for business expansion.
- Forming strategic partnerships with pharmaceutical companies or academic institutions can lead to joint research projects and access to new markets.
Threats
- Intense competition within the biotechnology industry may pose a threat to PolyPeptide Group AG's market share and profitability.
- Regulatory changes and stricter compliance requirements could increase operational costs or impact product development timelines.
- Fluctuations in the global economy and currency exchange rates can impact the company's financial performance, particularly in international markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.